BMS-986523
/ BMS
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 13, 2026
CA2560001: A Phase 1/2a Study of BMS-986523 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Malignancies
(clinicaltrialsregister.eu)
- P1/2 | N=16 | Not yet recruiting | Sponsor: Bristol-Myers Squibb Services Unlimited Company
Monotherapy • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS
December 18, 2025
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
(clinicaltrials.gov)
- P1/2 | N=252 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting
Enrollment open • Monotherapy • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor
November 01, 2025
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
(clinicaltrials.gov)
- P1/2 | N=252 | Not yet recruiting | Sponsor: Bristol-Myers Squibb
Monotherapy • New P1/2 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor
1 to 3
Of
3
Go to page
1